VPA25460/003/001

Dugmectin 18.7 mg/g Oral Paste for Horses

Variation	Summary	Date
Vet - C1	VNRA - Vet - C1 Vet - C1 - Change(s) in the name or address or	29/10/25
	contact details of a qualified person for pharmacovigilance (QPPV)	29/10/23
Vet - C6	VNRA - Vet - C6 Vet - C6 - Introduction of a summary of the	
	PSMF or changes to the summary of the PSMF not already covered	29/10/25
	elsewhere in this Annex	
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or	15/05/25
	changes to the summary of the PSMF not already covered elsewhere	
	in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety,	
	efficacy and pharmacovigilance part of the dossier: Introduction of a	
	summary of the PSMF or changes to the summary of the PSMF not	
	already covered elsewhere in the Annex to Regulation (EU) 2021/17	
Vet - B40	VNRA - Vet - B40 - Replacement or addition of a supplier of	09/01/25
	packaging components or devices - B40 Changes to the quality part	
	of the dossier: Replacement or addition of a supplier of packaging	
	components or devices (when mentioned in the dossier)	
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an	18/10/23
	active substance, intermediate or finished product, packaging site,	
	manufacturer responsible for batch release, site where batch control	
	takes place, or supplier of a starting material for an active substance,	
	reagent or excipient (when mentioned in the dossier) - B3 a) Changes	
	to the quality part of the dossier: Deletion of a manufacturing site for	
	an active substance, intermediate or finished product, packaging site,	
	manufacturer responsible for batch release, site where batch control	
	takes place, or supplier of a starting material for an active substance,	
	reagent or excipient (when mentioned in the dossier)	
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an	
	active substance, intermediate or finished product, packaging site,	11/10/23
	manufacturer responsible for batch release, site where batch control	
	takes place, or supplier of a starting material for an active substance,	
	reagent or excipient (when mentioned in the dossier) - B3 a) Changes	
	to the quality part of the dossier: Deletion of a manufacturing site for	
	an active substance, intermediate or finished product, packaging site,	
	manufacturer responsible for batch release, site where batch control	
	takes place, or supplier of a starting material for an active substance,	
	reagent or excipient (when mentioned in the dossier)	